跳至主要内容
临床试验/NL-OMON43279
NL-OMON43279已完成2 期

An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding - ROW

Maag-, darm- en leverziekten0 个研究点目标入组 11 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
11

研究概览

简要总结

Trial is onging in other countries

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Patients with Rendu-Osler-Weber;- Symptomatic gastrointestinal bleeds out of telangiectasias;- Transfusion and / or endoscopy dependent: ;Transfusion: at least 2 blood and/or iron infusions in the 6 months before inclusion.;Endoscopy: at least one endoscopy with APC after the initial endoscopic treatment after diagnosis in the half year before inclusion or unsuitable for endoscopy.

排除标准

  • - liver cirrhosis Child-Pugh C or acute liver failure
  • - Symptomatic cholecystolithiasis (without cholecystectomie)
  • - previous unsuccessful treatment with somatostatin analogues for the same indication (refractory anaemia due to telangiectasias) or current effective treatment with a somatostatin analogue
  • - current successful treatment with thalidomide
  • - severe diseases with life expectancy < 1 year
  • - patients with left ventricular assist devices (LVAD*s)
  • - pregnancy or nursing women or women who have a pregnancy wish in the studyperiod or who use anticonception inadequate
  • - current chemotherapy
  • - patients with a known hypersensitivity to SST analogues or any component of the pasireotide LAR formulations
  • - systemic cancer currently undergoing chemotherapy or radiation therapy
  • - no understanding of Dutch or English

研究者

发起方
Maag-, darm- en leverziekten

相似试验